199 related articles for article (PubMed ID: 10705871)
21. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
[TBL] [Abstract][Full Text] [Related]
22. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
24. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
25. Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women.
McIntyre R; Bigler L; Dellinger T; Pfeifer M; Mannery T; Streckfus C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Dec; 88(6):687-90. PubMed ID: 10625851
[TBL] [Abstract][Full Text] [Related]
26. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
27. Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.
Vahedi M; Abdollahzadeh S; Vaziri PB; Mortazavi H
Med Oral Patol Oral Cir Bucal; 2011 Jan; 16(1):e29-32. PubMed ID: 20711149
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
29. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
30. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.
Asgeirsson KS; Agrawal A; Allen C; Hitch A; Ellis IO; Chapman C; Cheung KL; Robertson JF
Breast Cancer Res; 2007; 9(6):R75. PubMed ID: 17976236
[TBL] [Abstract][Full Text] [Related]
31. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
33. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE
J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701
[TBL] [Abstract][Full Text] [Related]
34. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
35. Correlation of serum and salivary CA15-3 levels in patients with breast cancer.
Agha-Hosseini F; Mirzaii-Dizgah I; Rahimi A
Med Oral Patol Oral Cir Bucal; 2009 Oct; 14(10):e521-4. PubMed ID: 19680209
[TBL] [Abstract][Full Text] [Related]
36. Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women.
Farahani H; Amri J; Alaee M; Mohaghegh F; Rafiee M
Lab Med; 2020 Nov; 51(6):620-627. PubMed ID: 32537654
[TBL] [Abstract][Full Text] [Related]
37. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
38. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma.
Colomer R; Aparicio J; Montero S; Guzmán C; Larrodera L; Cortés-Funes H
Br J Cancer; 1997; 76(9):1215-20. PubMed ID: 9365172
[TBL] [Abstract][Full Text] [Related]
39. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2002; 9(2):111-7. PubMed ID: 12016390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
